ReviewJournal of molecular medicine (Berlin, Germany)2003
Proteasome inhibition: a new anti-inflammatory strategy.
Review in Journal of molecular medicine (Berlin, Germany), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- SkeletalVis: an exploration and meta-analysis data portal of cross-species skeletal transcriptomics data.Bioinformatics (Oxford, England) · 2019Pooled it
- Quantitative assessment of the influence of PSMA6 variant (rs1048990) on coronary artery disease risk.Molecular biology reports · 2013Pooled it
- Emerging perspectives in proteostasis: bridging mechanisms and therapeutics for human diseases.Signal transduction and targeted therapy · 2026Review
- Dermal Fibroblasts, Not Keratinocytes, Dominate IL-17A/TNF-Driven Inflammation.Experimental dermatology · 2026Article
- Article
- Screening of a Plant Extract Library from the Greek Flora for Biological Activities Related to Anti-Aging Applications.Antioxidants (Basel, Switzerland) · 2025Article
- Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro.Inflammopharmacology · 2024Review
- New Posttranslational Modification Lactylation Brings New Inspiration for the Treatment of Rheumatoid Arthritis.Journal of inflammation research · 2024Review
- Crosstalk between phytochemicals and inflammatory signaling pathways.Inflammopharmacology · 2023Review
- Covalent Inhibition of thePharmaceuticals (Basel, Switzerland) · 2022Article
- The Role of Immunoproteasomes in Tumor-Immune Cell Interactions in Melanoma and Colon Cancer.Archivum immunologiae et therapiae experimentalis · 2022Review
- Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.Inflammopharmacology · 2021Review
- Changes in Proteome of Fibroblasts Isolated from Psoriatic Skin Lesions.International journal of molecular sciences · 2020Article
- Exosomes derived from HeLa cells break down vascular integrity by triggering endoplasmic reticulum stress in endothelial cells.Journal of extracellular vesicles · 2020Article
- Roseltide rT7 is a disulfide-rich, anionic, and cell-penetrating peptide that inhibits proteasomal degradation.The Journal of biological chemistry · 2019Article
- Over-Activated Proteasome Mediates Neuroinflammation on Acute Intracerebral Hemorrhage in Rats.Cells · 2019Article
- Visualizing Proteasome Activity and Intracellular Localization Using Fluorescent Proteins and Activity-Based Probes.Frontiers in molecular biosciences · 2019Article
- Impact of proteasome inhibitor MG-132 on expression of NF-κB, IL-1β and histological remodeling after myocardial infarction.Experimental and therapeutic medicine · 2018Article
- Defining Host Responses during Systemic Bacterial Infection through Construction of a Murine Organ Proteome Atlas.Cell systems · 2018Article
- Identification of key genes and pathways for peri-implantitis through the analysis of gene expression data.Experimental and therapeutic medicine · 2017Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ubiquitin-proteasome pathway has a central role in the selective degradation of intracellular proteins. Among the key proteins modulated by the proteasome are those involved in the control of inflammatory processes, cell cycle regulation, and gene expression. Consequently proteasome inhibition is a potential treatment option for cancer and inflammatory conditions. Thus far, proof of principle has been obtained from studies in numerous animal models for a variety of human diseases including cancer, reperfusion injury, and inflammatory conditions such as rheumatoid arthritis, asthma, multiple sclerosis, and psoriasis. Two proteasome inhibitors, each representing a unique chemical class, are currently under clinical evaluation. Velcade (PS-341) is currently being evaluated in multiple phase II clinical trials for several solid tumor indications and has just entered a phase III trial for multiple myeloma. PS-519, representing another class of inhibitors, focuses on the inflammatory events following ischemia and reperfusion injury. Since proteasome inhibitors exhibit anti-inflammatory and antiproliferative effects, diseases characterized by both of these processes simultaneously, as is the case in rheumatoid arthritis or psoriasis, might also represent clinical opportunities for such drugs.
Indexed as
Identifiers
12700891What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.